In a reversal, the drugmaker Sarepta Therapeutics said July 21 it is stopping all shipments of a gene therapy that has been linked to multiple deaths.
Sarepta said in a statement it will voluntarily, and temporarily, halt all shipments of Elevidys at the close of business on July 22.
Elevidys is a gene therapy treatment for Duchenne muscular dystrophy, a disorder that is inherited and features weakening muscles and increasing difficulty moving.
There is no cure, but treatments and physical therapy can help control the condition.
Two non-ambulatory patients died after receiving Elevidys. The first death was reported in March and the second was reported by Sarepta in June. Sarepta then stopped shipments of Elevidys to non-ambulatory patients as it worked on a solution….